Skip to main content
Caplight Logo









Vima Therapeutics

Vima Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://vimatx.com/

Last Round

Series A

Mar 11, 2026

Total Funding Raised

$140M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Vima Therapeutics is a biotechnology company developing oral therapeutics designed for the treatment of movement disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverymovement disorderssmall-molecule therapyclinical trialsdystoniaParkinson's diseasebiotechneurologyoral therapypharmaclinical-stagedrug developmentmotor control

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vima Therapeutics Comparables

Compare Vima Therapeutics with similar companies based on industry and business-model similarity.

Vima Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Motric Bio
76%
Addex Therapeutics
76%
Neurocrine Biosciences
72%

Vima Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 11, 2026
Series AMay 29, 2025

Key People

Founding team and executive leadership

Bernard Ravina

Chief Executive Officer

Executive Team

Vima Therapeutics Investors

Notable investors and investment history

Vima Therapeutics investors
InvestorRounds
Access IndustriesSeries A
Frazier Life SciencesSeries A
Canaan PartnersSeries A
Atlas VentureSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 21, 2026

    Grew 16% QoQ, from 19 to 22 employees.

  • Apr 24, 2026

    Monthly visitors increased 303% MoM, reaching 2.4K.

Vima Therapeutics Filings

Explore SEC and related filing metadata, where available.

Vima Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Vima Therapeutics's valuation, stock price, and market status.

Is Vima Therapeutics a public or private company?

Vima Therapeutics is a private company.

What is the current stock price of Vima Therapeutics?

Vima Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Vima Therapeutics worth (valuation)?

Valuation information for Vima Therapeutics is not publicly available.

Can I buy Vima Therapeutics stock?

Vima Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Vima Therapeutics's last funding round?

Vima Therapeutics's most recent funding round was Series A on March 11, 2026.

Who are the main investors in Vima Therapeutics?

Key investors in Vima Therapeutics include Frazier Life Sciences, Atlas Venture.

Will Vima Therapeutics IPO soon?

No public IPO plans have been announced for Vima Therapeutics.

How can I track Vima Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Vima Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range24
Year Founded2023
Last FundingMar 11, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?